Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the
- PDF / 561,019 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 57 Downloads / 228 Views
ORIGINAL ARTICLE—LIVER, PANCREAS, AND BILIARY TRACT
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) Yuta Maruki1 • Chigusa Morizane1 • Yasuhito Arai2 • Masafumi Ikeda3 • Makoto Ueno4 • Tatsuya Ioka5 • Atsushi Naganuma6 • Masayuki Furukawa7 • Nobumasa Mizuno8 • Tadashi Uwagawa9 • Naminatsu Takahara10 • Masashi Kanai11 • Akinori Asagi12 • Satoshi Shimizu13 • Atsushi Miyamoto14 • Seigo Yukisawa15 • Makoto Kadokura16 • Yasushi Kojima17 • Junji Furuse18 • Takako Eguchi Nakajima19,20 • Kentaro Sudo21 • Noritoshi Kobayashi22 • Natsuko Hama2 • Takeharu Yamanaka23 • Tatsuhiro Shibata2 • Takuji Okusaka1 Received: 11 May 2020 / Accepted: 26 September 2020 Ó The Author(s) 2020
Abstract Background Fibroblast growth factor receptor 2 (FGFR2) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However,
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00535-020-01735-2) contains supplementary material, which is available to authorized users. & Chigusa Morizane [email protected]
efficient detection and the exact frequency of FGFR2 rearrangements among patients with advanced/recurrent BTC have not been determined, and the clinical characteristics of FGFR2 rearrangement-positive patients have not been fully elucidated. We aimed to determine the frequency of FGFR2 rearrangement-positive patients among those with advanced/recurrent BTC and elucidate their clinicopathological characteristics. 9
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
10
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
1
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
11
2
Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
12
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
13
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
14
Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
Department of Oncology Center, Yamaguchi University Hospital, Yamaguchi, Japan
15
Department of Medical Oncology, Tochigi Cancer Center, Tochigi, Japan
Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan
16
Department of Gastroenterology, Kofu Municipal Hospital, Yamanashi, Japan
17
Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
18
Department of Medical Oncology, Kyorin University Faculty of Medic
Data Loading...
